.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers are currently investigating Nifuroxazide Hepatocellular Carcinoma therapy to improve outcomes in advanced liver cancer. Hepatocellular carcinoma (HCC) often resists standard treatments due to an immunosuppressive microenvironment. Recently, a study introduced a biomimetic delivery system using macrophage-like cells. They loaded Nifuroxazide (NFX) into RAW264.7 cells to create a platform called Mφ-NFX. This innovative strategy effectively overcomes the drug's poor solubility. Furthermore, the macrophage carriers deliver the agent directly to tumor tissues without causing systemic toxicity.
Notably, Nifuroxazide acts as a potent inhibitor of STAT3 signaling. This inhibition is crucial because aberrant STAT3 activation drives chemoresistance in many tumors. Additionally, the macrophage delivery system reprograms the tumor microenvironment. It specifically promotes the polarization of macrophages toward the tumor-killing M1 phenotype. Consequently, the M1/M2 ratio increases, which actively suppresses tumor growth. This dual action significantly enhances the overall therapeutic effect in preclinical models.
Moreover, the combination of Mφ-NFX and Oxaliplatin demonstrates remarkable synergy. Mechanistically, this treatment inhibits the AKT/β-catenin signaling pathway. Therefore, this approach suppresses tumor progression more effectively than using oxaliplatin alone. Importantly, the macrophage-based platform shows high biocompatibility and target specificity. This finding suggests a promising future for using biomimetic drug delivery systems in clinical hepatology. Ultimately, this platform offers a path to sensitize resistant tumors to conventional chemotherapy.
Nifuroxazide inhibits the STAT3 signaling pathway. This inhibition reduces tumor growth, prevents immune evasion, and helps overcome resistance to drugs like oxaliplatin.
Nifuroxazide has poor oral solubility and low bioavailability. Using macrophages as biomimetic carriers ensures the drug is delivered directly to the tumor site, improving efficacy while minimizing side effects.
The combination synergistically inhibits the AKT/β-catenin pathway. This action prevents cancer cell proliferation and promotes a more active immune response within the tumor microenvironment.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Yang Z et al. Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy. J Nanobiotechnology. 2026 Feb 23. doi: 10.1186/s12951-026-04196-6. PMID: 41731511.
Li K et al. Regorafenib and Nifuroxazide exert enhanced suppression of hepatocellular carcinoma by inhibiting STAT3 and immune remodeling. J Cancer Res Clin Oncol. 2024.
Morelli M et al. Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition. MDPI. 2023.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers developed a biomimetic macrophage delivery system for Nifuroxazide to reprogram the tumor microenvironment and improve outcomes in liver cancer....
6 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
